Van Brummelen P, Bolli P, Koolen M I, Staehelin H B, Bühler F R
Br J Clin Pharmacol. 1984 Jan;17(1):86-8. doi: 10.1111/j.1365-2125.1984.tb05004.x.
The influence of bopindolol monotherapy on blood pressure and plasma lipid fractions was investigated in 24 hypertensive patients. Bopindolol lowered blood pressure and heart rate significantly. When compared with placebo no changes were found in the plasma concentrations of total cholesterol, LDL cholesterol and HDL cholesterol. Plasma triglycerides were significantly increased after 4 and 8 weeks but not after 12 weeks of bopindolol. It is concluded that bopindolol is an effective and well tolerated beta-adrenoceptor blocker in hypertensive patients. The fact that it does not lower HDL cholesterol could be a potential advantage.
在24例高血压患者中研究了波吲洛尔单一疗法对血压和血浆脂质成分的影响。波吲洛尔能显著降低血压和心率。与安慰剂相比,总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇的血浆浓度未发现变化。服用波吲洛尔4周和8周后血浆甘油三酯显著升高,但12周后未升高。结论是波吲洛尔在高血压患者中是一种有效且耐受性良好的β-肾上腺素能受体阻滞剂。它不降低高密度脂蛋白胆固醇这一事实可能是一个潜在优势。